DGAP-Ad-hoc: Limes Schlosskliniken AG / Key word(s): Preliminary Results/Results Forecast DGAP-Adhoc: Limes Schlosskliniken AG: Preliminary financial results LIMES Group 2021 (unaudited) - Outlook 2022 - Total revenue EUR 16.9m; (p. y. EUR 11.2m) +51 % - Gross earnings (EBITDA) +5,394 kEUR; (p. y. EUR +838 kEUR) - Operating result (EBIT) +3,505 kEUR; (p.y. EUR -427 kEUR) - Earning before tax (EBT) +3,284 kEUR; (p. y. -693 kEUR)
For 2022, including the consolidation of the Paracelsus Recovery Group, we expect sales of EUR 27.0m (+60%). The operating result (EBITDA) is expected to amount to approximately EUR 7.6m. We anticipate an operating result (EBIT) of EUR 5.4m. The budgeted figures for the 2022 financial year already take into account the start-up losses of EUR 1.3m for the new clinc "LIMES Schlossklinik Bergisches Land". The new clinic is scheduled to start operating on September 1, 2022. After a certain start-up phase, we expect additional sales of EUR 18.0m at 80 % capacity utilization. The LIMES Schlosskliniken Group operates high-quality private clinics in Germany for stress-related illnesses, mental and emotional disorders, such as depression, affective disorders and acute burnout conditions. The range of services is aimed at private patients, those entitled to state aid and self-payers. The LIMES Schlosskliniken Group stands for the special approach of a relationship-oriented medicine in the treatment of people with mental illnesses. In addition to top medical quality, patients are offered a unique, protected and healing environment in which they can recover holistically. Further information is available at www.limes-schlosskliniken.de.
18-Jan-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Limes Schlosskliniken AG |
Kaiser-Wilhelm-Ring 26 | |
50672 Köln | |
Germany | |
ISIN: | DE000A0JDBC7 |
WKN: | A0JDBC |
Listed: | Regulated Unofficial Market in Dusseldorf |
EQS News ID: | 1269881 |
End of Announcement | DGAP News Service |
|
1269881 18-Jan-2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.